全文获取类型
收费全文 | 2768721篇 |
免费 | 210962篇 |
国内免费 | 4606篇 |
专业分类
耳鼻咽喉 | 39476篇 |
儿科学 | 85535篇 |
妇产科学 | 71876篇 |
基础医学 | 406875篇 |
口腔科学 | 76904篇 |
临床医学 | 253180篇 |
内科学 | 532394篇 |
皮肤病学 | 56922篇 |
神经病学 | 223751篇 |
特种医学 | 110297篇 |
外国民族医学 | 933篇 |
外科学 | 418404篇 |
综合类 | 61490篇 |
现状与发展 | 3篇 |
一般理论 | 1060篇 |
预防医学 | 220635篇 |
眼科学 | 64489篇 |
药学 | 209223篇 |
5篇 | |
中国医学 | 5165篇 |
肿瘤学 | 145672篇 |
出版年
2018年 | 28179篇 |
2016年 | 24038篇 |
2015年 | 27045篇 |
2014年 | 38482篇 |
2013年 | 58274篇 |
2012年 | 79925篇 |
2011年 | 85106篇 |
2010年 | 49873篇 |
2009年 | 47062篇 |
2008年 | 80232篇 |
2007年 | 85865篇 |
2006年 | 86430篇 |
2005年 | 83981篇 |
2004年 | 81030篇 |
2003年 | 78303篇 |
2002年 | 77185篇 |
2001年 | 126256篇 |
2000年 | 130612篇 |
1999年 | 110155篇 |
1998年 | 31590篇 |
1997年 | 28464篇 |
1996年 | 28327篇 |
1995年 | 27289篇 |
1994年 | 25621篇 |
1993年 | 24047篇 |
1992年 | 89029篇 |
1991年 | 87816篇 |
1990年 | 85323篇 |
1989年 | 82404篇 |
1988年 | 76615篇 |
1987年 | 75522篇 |
1986年 | 71261篇 |
1985年 | 68081篇 |
1984年 | 51325篇 |
1983年 | 43727篇 |
1982年 | 26001篇 |
1981年 | 23215篇 |
1980年 | 21821篇 |
1979年 | 48360篇 |
1978年 | 34061篇 |
1977年 | 28342篇 |
1976年 | 27296篇 |
1975年 | 29401篇 |
1974年 | 35757篇 |
1973年 | 33914篇 |
1972年 | 31762篇 |
1971年 | 29419篇 |
1970年 | 27681篇 |
1969年 | 25663篇 |
1968年 | 23510篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Sex hormone implants have been available for almost 50 years, but only a few clinicians administer them regularly. Implants represent a physiologic mode of therapy with many metabolic advantages over other routes. Surprisingly, they are relatively ignored by physicians. This may well reflect their surgical nature, although the technique of hormone implantation is simple and fast and obviates daily oral medication. As the list of indications for hormone pellets grows, more patients will take advantage of the benefits they offer. 相似文献
992.
993.
994.
Kenneth K. H. Chao BS Eric Cheung BS William B. Armstrong MD Brian J. F. Wong MD 《Otolaryngology--head and neck surgery》2002,126(6):593
Objective: The study goal was to compare the laser spot size created using reflective and refractive micromanipulators with a CO2 laser and to determine the sensitivity of spot size to laser power. Study Design and Setting: A CO2 laser and operating microscope (400-mm focal length) was coupled to either a reflective (Cassegrain-like) or refractive micromanipulator. Laser spot size was determined by measuring the region of ablation created by laser irradiation of wood (dry tongue depressors), exposed photographic film, and agar gel using optical micrometry. Laser power varied from 0.5 to 20 W with pulse durations of 0.1 and 0.5 second. Results: The reflective micromanipulator demonstrated overall smaller spot sizes for a given laser power and lower incremental change in spot size with increasing power. The reflective design demonstrated less sensitivity to increases in laser power. Conclusions: Micromanipulator optical design can result in significant differences in laser spot size. The reflective device used in this study demonstrated less sensitivity to increasing laser power. (Otolaryngol Head Neck Surg 2002;126:593-597.) 相似文献
995.
996.
997.
Ming Zhao Cheng Simon C F Rawlinson Andrew A Pitsillides Gul Zaman Subburaman Mohan David J Baylink Lance E Lanyon 《Journal of bone and mineral research》2002,17(4):593-602
The mechanism by which mechanical strain and estrogen stimulate bone cell proliferation was investigated using monolayer cultures of human osteoblastic TE85 cells and female human primary (first-passage) osteoblasts (fHOBs). Both cell types showed small but statistically significant dose-dependent increases in [3H]thymidine incorporation in response to 17beta-estradiol and to a single 10-minute period of uniaxial cyclic strain (1 Hz). In both cell types, the peak response to 17beta-estradiol occurred at 10(-8) - 10(-7) M and the peak response to strain occurred at 3500 microstrain ((mu)epsilon). Both strain-related and 17beta-estradiol-related increases in [3H]thymidine incorporation were abolished by the estrogen receptor (ER) modulator ICI 182,780 (10-8 M). Tamoxifen (10(-9) - 10(-8) M) increased [3H]thymidine incorporation in both cell types but had no effect on their response to strain. In TE85 cells, tamoxifen reduced the increase in [3H]thymidine incorporation associated with 17beta-estradiol to that of tamoxifen alone but had no such effect in fHOBs. In TE85 cells, strain increased medium concentrations of insulin-like growth factor (IGF) II but not IGF-I, whereas 17beta-estradiol increased medium concentrations of IGF-I but not IGF-II. Neutralizing monoclonal antibody (MNAb) to IGF-I (3 microg/ml) blocked the effects of 17beta-estradiol and exogenous truncated IGF-I (tIGF-I; 50 ng/ml) but not those of strain or tIGF-II (50 ng/ml). Neutralizing antibody to IGF-II (3 microg/ml) blocked the effects of strain and tIGF-II but not those of 17beta-estradiol or tIGF-I. MAb aIR-3 (100 ng/ml) to the IGF-I receptor blocked the effects on [3H]thymidine incorporation of strain, tIGF-II, 17beta-estradiol, and tIGF-I. HOBs and TE85 cells, act similarly to rat primary osteoblasts and ROS 17/2.8 cells in their dose-related proliferative responses to strain and 17beta-estradiol, both of which can be blocked by the ER modulator ICI 182,780. In TE85 cells (as in rat primaries and ROS 17/2.8 cells), the response to 17beta-estradiol is mediated by IGF-I, and the response to strain is mediated by IGF-II. Human cells differ from rat cells in that tamoxifen does not block their response to strain and reduces the response to 17beta-estradiol in TE85s but not primaries. In both human cell types (unlike rat cells) the effects of strain and IGF-II as well as estradiol and IGF-I can be blocked at the IGF-I receptor. 相似文献
998.
999.
M Hansrani K Overbeck J Smout G Stansby 《European journal of vascular and endovascular surgery》2002,24(5):377-382
INTRODUCTION: Intravascular brachytherapy (IVBT) utilises the percutaneous insertion of a radioactive source to inhibit myointimal hyperplasia in arteries treated by balloon angioplasty or stenting. A systematic review was performed of trials of IVBT in patients with Peripheral Arterial Disease (PAD). METHODS: Search strategy - the reviewers searched Medline, Embase, the Cochrane Peripheral Vascular Diseases Group trials register, DARE, CCT and NHS EED for clinical studies and trials of adjuvant IVBT in PAD. Two reviewers assessed trial quality independently. RESULTS: Fourteen clinical trials were identified by the search, representing five clinical studies (all allocated D for not randomised) and one randomised controlled trial (allocated A). The randomised trial showed a benefit for IVBT compared with placebo (OR 0.35, 95% CI 0.24-0.53). In the non-randomised studies, 12 month cumulative patency rates ranged from 60-87%. There were few technical complications. In the only report involving IVBT and routine concurrent stent insertion acute thrombosis occurred in 7 (21%) of patients. CONCLUSION: Early reports have confirmed the safety and technical feasibility of IVBT. However, follow-up is too short at present to assess the durability and long-term complications of this new therapeutic option. 相似文献
1000.